Here are the 10-K annual reports from Sunshine Biopharma Inc. warrant (SBFMW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SBFMW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SBFMW filings page.
Sunshine Biopharma Inc. reported 2025 revenue of $36,305,891, up from $34,874,283 in 2024, driven mainly by expanded Canadian generic drug sales through its Nora Pharma subsidiary. Cost of sales was $24,050,214, yielding gross profit of $12,255,677.
The company remains unprofitable, recording a 2025 net loss of $5,975,352 and an accumulated deficit of $75,015,126, though operating cash use declined versus 2024. Sunshine ended 2025 with $9,123,308 in cash and believes this will fund operations for about 18 months. Its portfolio includes 71 generic drugs in Canada, 22 pipeline generics, OTC supplements, and two proprietary programs (K1.1 mRNA for liver cancer and SBFM-PL4, a PLpro inhibitor for SARS coronavirus) in animal testing. In December 2025 it received a USPTO Notice of Allowance for its coronavirus protease inhibitor patent, and it holds trademarks for “Sunshine Biopharma Inc.” in the U.S. and Canada.